J Korean Med Sci.  2010 Mar;25(3):387-392. 10.3346/jkms.2010.25.3.387.

Post-Prandial Lipid Levels for Assessing Target Goal Achievement in Type 2 Diabetic Patients Taking Statin

• Kim M
• Suk J
• Kim H
• Jung H
• Kim T
• Park J

• KMID: 1778033
• DOI: http://doi.org/10.3346/jkms.2010.25.3.387

Abstract

It is inconvenient to perform serum lipid analysis in fasting state in diabetic patients with drug treatment. In patients with statin treatment and Asian diet, it has not been clearly known whether non-fasting values could be used for the clinical decision making in diabetic patients. In this study, fasting and post-prandial plasma lipid profiles of hospitalized type 2 diabetic patients taking statin, were measured in whom standard diabetic breakfast in traditional Korean style were provided. In repeated-measures ANOVA, there were no significant differences among fasting, post-prandial 2 and 4 hr low-density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol values. When compared to fasting levels, both post-prandial 2 hr and 4 hr LDL cholesterol levels were misclassified as not achieved target goal only in 4% of patients. Post-prandial HDL cholesterol matched with fasting values in women, without exception. In conclusion, the fasting and post-prandial LDL and HDL cholesterol levels are not significantly different each other and can be used in the assessment of achieving target goal in type 2 diabetes taking statin after Korean diet.

Keyword

Fasting; Postprandial Period; Lipid Goal; Diabetes Mellitus, Type 2; Korean Diet

MeSH Terms

Aged
Cholesterol, HDL/*blood
Cholesterol, LDL/*blood
Diabetes Mellitus, Type 2/*blood/drug therapy
Diet
Fasting
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
Korea
Male
Middle Aged
*Postprandial Period
Pregnancy

Figure

• 

  Fig. 1 Changes in fasting and post-prandial 2- and 4-hr lipid values. (A) total cholesterol, (B) triglyceride, (C) LDL cholesterol, (D) HDL cholesterol. *P<0.05 compared to fasting value by repeated measure test.

Reference

1. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care. 2008. 31:Suppl 1. S12–S54.

2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001. 285:2486–2497.

3. Bottorff MB. Underidentification and undertreatment issues. J Manag Care Pharm. 2003. 9:6–8.

4. Kolding Kristensen J, Lauritzen T. Inadequate treatment of dyslipidemia in people with type 2 diabetes: quality assessment of diabetes care in a Danish County. Scand J Prim Health Care. 2006. 24:181–185.

5. Primatesta P, Poulter NR. Levels of dyslipidemia and improvement in its management in England: results from the Health Survey for England 2003. Clin Endocrinol (Oxf). 2006. 64:292–298.

6. Weiss R, Harder M, Rowe J. The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Ther. 2003. 25:1490–1497.

7. Schaefer EJ, Audelin MC, McNamara JR, Shah PK, Tayler T, Daly JA, Augustin JL, Seman LJ, Rubenstein JJ. Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease. Am J Cardiol. 2001. 88:1129–1133.

8. Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JA, Seman LJ, Ferrari A, Rubenstein JJ. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol. 2002. 90:689–696.

9. Wilder LB, Bachorik PS, Finney CA, Moy TF, Becker DM. The effect of fasting status on the determination of low-density and high-density lipoprotein cholesterol. Am J Med. 1995. 99:374–377.

10. Dungan KM, Guster T, DeWalt DA, Buse JB. A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes. Curr Med Res Opin. 2007. 23:2689–2695.

11. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screeners of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986. 256:2823–2828.

12. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994. 344:1383–1389.

13. Shepherd J. Preventing coronary artery disease in the West of Scotland: implications for primary prevention. Am J Cardiol. 1998. 82(10B):57T–59T.

14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002. 360:7–22.

15. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: executive summary of the Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Cardiovasc Prev Rehabil. 2003. 10:S1–S10.

16. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet. 2001. 357:995–1001.

17. Pearson TA, Laurora I, Chu H. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000. 160:459–467.

18. Frolkis JP, Zyzanski SJ, Schwartz JM, Suhan PS. Physician non-compliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation. 1998. 98:851–855.

19. Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S, Yin D. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin. 2005. 21:1389–1399.

20. Euro Heart Survey Programme. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II. Eur Heart J. 2001. 22:554–572.

21. Dubois C, Beaumier G, Juhel C, Armand M, Portugal H, Pauli AM, Borel P, Latge C, Lairon D. Effects of graded amounts (0-50 g) of dietary fat on postprandial lipemia and lipoproteins in normolipidemic adults. Am J Clin Nutr. 1998. 67:31–38.

22. Williams PT, Blanche PJ, Rawlings R, Krauss RM. Concordant lipoprotein and weight responses to dietary fat change in identical twins with divergent exercise levels 1. Am J Clin Nutr. 2005. 82:181–187.

23. Hayek T, Ito Y, Azrolan N, Verdery RB, Aalto-Setälä K, Walsh A, Breslow JL. Dietary fat increases high density lipoprotein (HDL) levels both by increasing the transport rates and decreasing fractional catabolic rates of HDL cholesterol ester and apolipoprotein (apo) A-I. Presentation of a new animal model and mechanistic studies in human Apo A-I transgenic and control mice. J Clin Invest. 1993. 91:1665–1671.

24. Volek JS, Sharman MJ, Gómez AL, DiPasquale C, Roti M, Pumerantz A, Kraemer WJ. Comparison of a very low-carbohydrate and low-fat diet on fasting lipids, LDL subclasses, insulin resistance, and postprandial lipemic responses in overweight women. J Am Coll Nutr. 2004. 23:177–184.

25. Hegsted DM, Kritchevsky D. Diet and serum lipid concentrations: where are we? Am J Clin Nutr. 1997. 65:1893–1896.

26. Lund SS, Tarnow L, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag AA. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. Eur J Endocrinol. 2008. 158:35–46.